Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.43 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 11/20 | 0.39 |
| ▸ | CA2 | P00918 | 11/20 | 0.39 |
| ▸ | CA4 | P22748 | 11/20 | 0.39 |
| ▸ | CA9 | Q16790 | 11/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | USP19 | O94966 | 1/20 | 0.37 |
| ▸ | USP7 | Q93009 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8236501 | 0.93 | ABHD6 (0.42) | ABHD6DAGLANR1H2NR1H3CA1 | |
| SCHEMBL8235657 | 0.92 | ABHD6 (0.41) | ABHD6DAGLANR1H2NR1H3CA1 | |
| SCHEMBL3491838 | 0.91 | CA1 (0.42) | CA1CA2CA4CA9USP7 | |
| SCHEMBL8236128 | 0.90 | ABHD6 (0.43) | ABHD6DAGLACA1CA2CA4 | |
| SCHEMBL8238147 | 0.90 | ABHD6 (0.43) | ABHD6DAGLANR1H2NR1H3CA1 | |
| SCHEMBL8235940 | 0.89 | ABHD6 (0.44) | ABHD6DAGLANR1H2NR1H3CA1 | |
| SCHEMBL8237203 | 0.89 | ABHD6 (0.44) | ABHD6DAGLANR1H2NR1H3CA1 | |
| SCHEMBL8231279 | 0.87 | ABHD6 (0.40) | ABHD6DAGLANR1H2NR1H3CA1 | |
| SCHEMBL8238575 | 0.85 | ABHD6 (0.42) | ABHD6DAGLANR1H2NR1H3CA1 | |
| SCHEMBL4978691 | 0.85 | ABHD6 (0.42) | ABHD6DAGLANR1H2NR1H3PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
| WO-2007094513-A2 | CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | REN, AGTR1, AGTR2 | ABHD6 2780/4885DAGLA 4388/4885NR1H2 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.